Search Result

Results for "

resorption

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Akt (8) Antibiotic (2) Apoptosis (33) Autophagy (1) Bacterial (7) Biochemical Assay Reagents (1) Btk (1) c-Fms (1) Calcium Channel (1) CaMK (1) Caspase (3) CaSR (2) Cathepsin (9) CDK (2) CGRP Receptor (4) Chloride Channel (2) COX (4) CXCR (1) Cytochrome P450 (2) DOCK (1) Drug Derivative (4) Drug Intermediate (1) Drug Metabolite (1) Endogenous Metabolite (13) Environmental Pollutants (3) ERK (6) Estrogen Receptor/ERR (2) Farnesyl Transferase (4) Fungal (2) GABA Receptor (1) Glutathione Peroxidase (1) GSK-3 (2) Heme Oxygenase (HO) (4) Histone Methyltransferase (1) HIV (1) Influenza Virus (1) Integrin (6) Interleukin Related (7) Isotope-Labeled Compounds (5) JNK (7) Keap1-Nrf2 (6) Lipoxygenase (1) LRRK2 (1) MMP (4) mTOR (4) NF-κB (17) NO Synthase (4) NOD-like Receptor (NLR) (2) Nuclear Factor of activated T Cells (NFAT) (4) P2X Receptor (1) p38 MAPK (7) Parasite (5) PDGFR (1) Phosphatase (3) Phosphodiesterase (PDE) (1) PI3K (9) PKC (1) Potassium Channel (1) PPAR (2) Progesterone Receptor (3) PROTACs (1) Proton Pump (4) PTHR (2) RANKL/RANK (13) Ras (1) Reactive Oxygen Species (ROS) (5) Reference Standards (21) Ser/Thr Protease (1) SOD (2) Src (1) STAT (1) TGF-beta/Smad (4) TGF-β Receptor (1) Thyroid Hormone Receptor (3) TNF Receptor (2) VD/VDR (5) VEGFR (2) VSV (1) Wee1 (2) Wnt (3) β-catenin (3)
By Research Areas:	Cancer (48) Cardiovascular Disease (11) Endocrinology (9) Infection (14) Inflammation/Immunology (38) Metabolic Disease (80) Neurological Disease (10)

By Targets:

Adrenergic Receptor (1)

Akt (8)

Antibiotic (2)

Apoptosis (33)

Autophagy (1)

Bacterial (7)

Biochemical Assay Reagents (1)

Btk (1)

c-Fms (1)

Calcium Channel (1)

CaMK (1)

Caspase (3)

CaSR (2)

Cathepsin (9)

CDK (2)

CGRP Receptor (4)

Chloride Channel (2)

COX (4)

CXCR (1)

Cytochrome P450 (2)

DOCK (1)

Drug Derivative (4)

Drug Intermediate (1)

Drug Metabolite (1)

Endogenous Metabolite (13)

Environmental Pollutants (3)

ERK (6)

Estrogen Receptor/ERR (2)

Farnesyl Transferase (4)

Fungal (2)

GABA Receptor (1)

Glutathione Peroxidase (1)

GSK-3 (2)

Heme Oxygenase (HO) (4)

Histone Methyltransferase (1)

HIV (1)

Influenza Virus (1)

Integrin (6)

Interleukin Related (7)

Isotope-Labeled Compounds (5)

JNK (7)

Keap1-Nrf2 (6)

Lipoxygenase (1)

LRRK2 (1)

MMP (4)

mTOR (4)

NF-κB (17)

NO Synthase (4)

NOD-like Receptor (NLR) (2)

Nuclear Factor of activated T Cells (NFAT) (4)

P2X Receptor (1)

p38 MAPK (7)

Parasite (5)

PDGFR (1)

Phosphatase (3)

Phosphodiesterase (PDE) (1)

PI3K (9)

PKC (1)

Potassium Channel (1)

PPAR (2)

Progesterone Receptor (3)

PROTACs (1)

Proton Pump (4)

PTHR (2)

RANKL/RANK (13)

Ras (1)

Reactive Oxygen Species (ROS) (5)

Reference Standards (21)

Ser/Thr Protease (1)

SOD (2)

Src (1)

STAT (1)

TGF-beta/Smad (4)

TGF-β Receptor (1)

Thyroid Hormone Receptor (3)

TNF Receptor (2)

VD/VDR (5)

VEGFR (2)

VSV (1)

Wee1 (2)

Wnt (3)

β-catenin (3)

By Research Areas:

Cancer (48)

Cardiovascular Disease (11)

Endocrinology (9)

Infection (14)

Inflammation/Immunology (38)

Metabolic Disease (80)

Neurological Disease (10)

145

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0090

Calcitonin (salmon) 2 Publications Verification Salmon calcitonin	CGRP Receptor	Cancer
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.

HY-P2273

Calcitonin (human)	CGRP Receptor	Metabolic Disease
Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .

HY-P9958

Denosumab 2 Publications Verification AMG-162	NF-κB Caspase Apoptosis RANKL/RANK	Endocrinology Cancer
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .

HY-B0631

Alendronic acid 5+ Cited Publications	NF-κB Interleukin Related	Metabolic Disease
Alendronate acid is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate acid induces skeletal alterations in the chicken embryonic development model. Alendronate acid can be used for osteoporosis research .

HY-128140

Z-FY-CHO 5+ Cited Publications Z-Phe-Tyr-CHO	Cathepsin	Neurological Disease Metabolic Disease
Z-FY-CHO (Z-Phe-Tyr-CHO) is a potent and specific cathepsin L (CTSL) inhibitor .

HY-B0657A

Clodronic acid disodium salt 4 Publications Verification Clodronate disodium salt	Apoptosis	Metabolic Disease Cancer
Clodronic acid (Clodronate) disodium salt is an orally active bisphosphonate. Clodronic acid disodium salt inhibits osteoclast-mediated bone resorption. Clodronic acid disodium salt reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid disodium salt is effective in the maintenance or improvement of bone mineral density. Clodronic acid disodium salt can be used for the research of multiple myeloma and postmenopausal osteoporosis .

HY-108685

Alendronate sodium 5+ Cited Publications Alendronic acid monosodium salt	NF-κB Interleukin Related	Metabolic Disease
Alendronate sodium is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate sodium induces skeletal alterations in the chicken embryonic development model. Alendronate sodium can be used for osteoporosis research .

HY-B0302

Etidronic acid 1 Publications Verification Etidronate; HEDPA; HEDP	Environmental Pollutants Apoptosis	Metabolic Disease Cancer
Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .

HY-A0020

Eldecalcitol 4 Publications Verification ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3	VD/VDR Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .

HY-B0302A

Etidronic acid disodium 1 Publications Verification Etidronate disodium; HEDPA disodium; HEDP disodium	Apoptosis	Metabolic Disease Cancer
Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .

HY-B0148

Risedronic acid 2 Publications Verification Risedronate	Parasite Apoptosis	Infection Metabolic Disease Cancer
Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC₅₀ of 20.3 μM) .

HY-N2532

Diphyllin 3 Publications Verification	VSV HIV Proton Pump Influenza Virus	Infection Inflammation/Immunology Cancer
Diphyllin is an orally active V-ATPase inhibitor (IC₅₀=17 nM) and HIV-1 inhibitor (IC₅₀=0.38 μM). Diphyllin blocks the acidification of osteoclast lysosomes and bone resorption lacunas (IC₅₀=0.6 nM for acid influx inhibition)， thereby inhibiting bone resorption. Diphyllin can effectively inhibit osteoclast-mediated bone resorption and has no effect on osteoblastic bone formation. Diphyllin can be used in the research of bone metabolism-related diseases and has the potential to inhibit diseases related to excessive bone resorption .

HY-N0257

Epimedin A 4 Publications Verification	PI3K Akt NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Heme Oxygenase (HO) SOD Caspase Interleukin Related	Metabolic Disease Inflammation/Immunology
Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases .

HY-B1246

Thonzonium bromide 5+ Cited Publications	Bacterial Proton Pump	Infection
Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC₅₀=69 μM) .

HY-110318

VUF11207 fumarate 3 Publications Verification	CXCR	Inflammation/Immunology Cancer
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .

HY-N6084

Humulone α-Lupulic acid	COX GABA Receptor Apoptosis	Cardiovascular Disease
Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent cyclooxygenase-2 (COX-2) inhibitor. Humulone acts as a positive modulator of GABA_A receptor at low micromolar concentrations. Humulone is an inhibitor of bone resorption. Humulone possesses antioxidant, anti-angiogenic and apoptosis-inducing properties .

HY-12398

TEI-9647 2 Publications Verification	VD/VDR	Metabolic Disease Inflammation/Immunology
TEI-9647, a Vitamin D₃ Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)₂D₃. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)₂D₃. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .

HY-B0119

Risedronic acid sodium 2 Publications Verification Risedronate sodium	Parasite Apoptosis	Infection Metabolic Disease Cancer
Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC₅₀ of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins .

HY-114275

Justicidin B	Fungal Parasite Apoptosis	Infection Cardiovascular Disease Cancer
Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation .

HY-P0322

GRGDSPK EMD 56574	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .

HY-103352

L-006235 L-235	Cathepsin	Metabolic Disease
L-006235 (L-235) is a potent, selective, reversible and orally active inhibitor of cathepsin K, with an IC₅₀ of 5 nM in bone resorption assay. L-006235 shows selectivity for cathepsin K (K_i=0.2 nM) over cathepsin B, cathepsin L, and cathepsin S (K_i=1, 6, and 47 μM, respectively). L-006235 can reduce collagen degradation and prevent bone loss .

HY-N0094

Ipriflavone 2 Publications Verification	Cytochrome P450	Metabolic Disease Cancer
Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.

HY-B2162B

Chondroitin sulfate sodium (from bovine) Chondroitin polysulfate sodium (from bovine)	Reactive Oxygen Species (ROS) Endogenous Metabolite	Inflammation/Immunology
Chondroitin sulfate (Chondroitin polysulfate) sodium (from bovine)) is a sulfated linear polysaccharide extracted from bovine sources, belonging to glycosaminoglycans. Chondroitin sulfate sodium (from bovine) inhibits osteoclast-mediated bone resorption and exhibits antioxidant activity, which is negatively correlated with molecular weight. Chondroitin sulfate sodium (from bovine) can be used in studies related to osteoarthritis .

HY-17397

Strontium Ranelate 2 Publications Verification Distrontium renelate; S12911	CaSR	Metabolic Disease
Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling .

HY-10294

Relacatib SB-462795	Cathepsin	Metabolic Disease Cancer
Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with K_i values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC₅₀ values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .

HY-B0657

Clodronic acid 4 Publications Verification Clodronate	Apoptosis	Metabolic Disease Cancer
Clodronic acid (Clodronate) is an orally active bisphosphonate. Clodronic acid inhibits osteoclast-mediated bone resorption. Clodronic acid reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid is effective in the maintenance or improvement of bone mineral density. Clodronic acid can be used for the research of multiple myeloma and postmenopausal osteoporosis .

HY-W423191

Maltobionic acid 4-O-α-D-Glucopyranosyl-D-gluconic acid	Nuclear Factor of activated T Cells (NFAT) Bacterial	Infection Metabolic Disease
Maltobionic acid (4-O-α-D-Glucopyranosyl-D-gluconic acid) is an orally active oligosaccharide and iron chelator with antibacterial activity. Maltobionic acid inhibits the expression of NFATc1, suppresses osteoclast differentiation, inhibits bone resorption, and increases serum calcitonin levels. Maltobionic acid protects mammalian cells from hydrogen peroxide (H₂O₂)-induced oxidative damage; resists fermentation by the gut microbiota; and exhibits anti-digestive and anti-fermentative properties. Maltobionic acid can be used in research related to osteoporosis, bacterial infections, and constipation .

HY-A0020S

Eldecalcitol-d6	VD/VDR	Metabolic Disease
Eldecalcitol-d₆ is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.

HY-N1956

Rubiadin-1-methyl ether 1 Publications Verification	NF-κB	Metabolic Disease
Rubiadin-1-methyl ether is a natural anthraquinone isolated from Morinda officinalis How, and inhibits osteoclastic bone resorption via inhibition on the phosphorylation of NF-κB p65 and the degradation of IκBα as well as decrease in the nuclear translocation of p65 .

HY-P1189

Echistatin	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁ .

HY-N9331

Cimicifugoside H-1 Cimicidanol-3-O-β-d-xyloside	Others	Metabolic Disease
Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .

HY-N10117

2,3-Bis(3-indolylmethyl)indole	RANKL/RANK	Others
2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.

HY-P1189A

Echistatin TFA	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁ .

HY-16322

Minodronic acid 1 Publications Verification YM-529	P2X Receptor Apoptosis Farnesyl Transferase	Metabolic Disease Cancer
Minodronic acid is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .

HY-P1418A

DPC-AJ1951 TFA	Thyroid Hormone Receptor	Endocrinology
DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 TFA in ex vivo and in vivo assays of bone resorption .

HY-123370

FR-167356	Proton Pump	Metabolic Disease Cancer
FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC₅₀ values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .

HY-113230B

Galactosylhydroxylysine hydrochloride 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
Galactosylhydroxylysine hydrochloride is a component of bone collagen produced by post-translational glycosylation of hydroxylysine. Galactosylhydroxylysine hydrochloride is released during bone resorption and has been shown to be elevated in metabolic bone loss .

HY-N7646

Curculigoside B	Others	Others
Curculigoside B, a phenolic glycoside isolated from Curculigo orchioides, enhances the osteoblast proliferation, decreases the area of bone resorption pit, osteoclastic formation and TRAP activity. Antiosteoporotic and antioxidative activities .

HY-119868

Butaxamine Butoxamin	Adrenergic Receptor	Metabolic Disease
Butaxamine (Butoxamin) is a potent, selective and orally active β2-adrenoceptor antagonist. Butaxamine shows antiosteoporotic activity .

HY-149149

Incadronic acid	Bacterial	Infection Metabolic Disease Cancer
Incadronic acid inhibits growth of Dictyostelium discoideum with an IC₅₀ of 1.6 μM. Incadronic acid binds the farnesyl diphosphate synthase (FPPS) in Leishmania major with the K_i of 23 nM. Incadronic acid inhibits the bone resorption and reduces bone loss, that can be used in osteoporosis research. Incadronic acid inhibits the proliferation of cells RAW264.7, PC-3 and MCF-7 with IC₅₀ of 48 to 228.6 µM .

HY-P0284A

C-telopeptide TFA	MMP	Inflammation/Immunology
C-telopeptide TFA, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD) .

HY-P1288

Protein Kinase C (530-558) PKC fragment (530-558)	PKC	Others
Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .

HY-129337

Reveromycin A	Antibiotic Fungal Apoptosis	Infection Cancer
Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity .

HY-N5023

Veraguensin	Others	Metabolic Disease
Veraguensin is a lignan compound derived from Magnolia sp.. Veraguensin can inhibit bone resorption

HY-P0284

C-telopeptide	MMP	Inflammation/Immunology
C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).

HY-P4798

Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) Human PTHrP(107-111) amide	PTHR	Others
Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) (Human PTHrP (107-111) amide) is a C-terminal parathyroid hormone-related protein fragment that can inhibit bone resorption .

HY-B0631S

Alendronic acid-d6	Isotope-Labeled Compounds	Cancer
Alendronic acid-d₆ is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .

HY-50887

L-873724	Cathepsin	Metabolic Disease
L-873724 is a potent, orally bioavailable, selective and reversible non-basic cathepsin K inhibitor, with IC₅₀s of 0.2, 178, 264, and 5239 nM for cathepsin K, cathepsin S, cathepsin L, cathepsin B, respectively . L-873724 also exhibits an IC₅₀ of 0.5 nM for rabbit cathepsin K. L-873724 inhibits bone resorption .

HY-W107722

IN04	LRRK2	Endocrinology
IN04 is a inhibitor of leucine-rich repeat kinase 1 (LRRK1). IN04 can completely block the binding of ATP to the human LRRK1 kinase domain, thereby inhibiting the kinase activity of LRRK1. IN04 can significantly impair the bone resorption ability of osteoclasts, with an IC₅₀ value of 5.72 μM. IN04 can be used for the study of osteoporosis .

HY-B0148R

Risedronic acid (Standard) Risedronate (Standard)	Parasite Reference Standards Apoptosis	Infection Metabolic Disease Cancer
Risedronic acid (Standard) (Risedronate (Standard)) is the analytical standard of Risedronic acid (HY-B0148). This product is intended for research and analytical applications. Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC₅₀ of 20.3 μM).

Cat. No.	Product Name

HY-L926

Cysteine Protease Focused Covalent Library

2,114 compounds

Cysteine proteases (CPs), a key enzyme family regulating physiological metabolism and mediating pathological processes (e.g., abnormal bone resorption, tumour invasion, and pathogen infection), represent a core therapeutic target for disease intervention via the development of specific inhibitors. Currently reported CP covalent inhibitors encompass diverse structural types, including epoxides, aziridine, and activated double bonds (vinyl sulphones, α,β-unsaturated ketones), providing clear structural references for the development of novel CP covalent inhibitors.

This compound library contains multiple warheads that specifically target cysteine proteases, serving as a powerful tool for the efficient discovery of novel covalent inhibitors against this enzyme family.

HY-L925

Cysteine Protease Focused Library

9,192 compounds

Cysteine proteases (CPs), a key enzyme family regulating physiological metabolism and mediating pathological processes (such as abnormal bone resorption, tumour invasion, and pathogen infection), represent a core therapeutic target for developing specific inhibitors in disease intervention. Currently reported CP inhibitors primarily achieve their inhibitory function by precisely binding to CP active pockets (e.g., S1-S4 non-primed regions or S1'-S2' primed regions) and forming covalent/non-covalent interactions with the active site cysteine residues, providing clear structural references for the development of novel inhibitors.

This compound library, designed based on the core strategy of "similarity-based known active structures", contains over 200 cysteine protease inhibitors. Leveraging AI-driven molecular screening technology, it retains the critical pharmacological and shape features of reported CP inhibitors, serving as a specialized tool for efficiently discovering novel cysteine protease inhibitors.

Cat. No.	Product Name	Type

HY-B2162B

Chondroitin sulfate sodium (from bovine)

Chondroitin polysulfate sodium (from bovine)

Biochemical Assay Reagents

Chondroitin sulfate (Chondroitin polysulfate) sodium (from bovine)) is a sulfated linear polysaccharide extracted from bovine sources, belonging to glycosaminoglycans. Chondroitin sulfate sodium (from bovine) inhibits osteoclast-mediated bone resorption and exhibits antioxidant activity, which is negatively correlated with molecular weight. Chondroitin sulfate sodium (from bovine) can be used in studies related to osteoarthritis .

HY-W423191

Maltobionic acid

4-O-α-D-Glucopyranosyl-D-gluconic acid

Biochemical Assay Reagents

Maltobionic acid (4-O-α-D-Glucopyranosyl-D-gluconic acid) is an orally active oligosaccharide and iron chelator with antibacterial activity. Maltobionic acid inhibits the expression of NFATc1, suppresses osteoclast differentiation, inhibits bone resorption, and increases serum calcitonin levels. Maltobionic acid protects mammalian cells from hydrogen peroxide (H₂O₂)-induced oxidative damage; resists fermentation by the gut microbiota; and exhibits anti-digestive and anti-fermentative properties. Maltobionic acid can be used in research related to osteoporosis, bacterial infections, and constipation .

HY-W145486

Calcium gluconate

Biochemical Assay Reagents

Calcium gluconate is an orally effective calcium salt supplement . Calcium gluconate reduces elevated serum potassium, decreased serum calcium, and postoperative myalgia associated with succinylcholine administration. Calcium gluconate restores calcium homeostasis, skeletal integrity, bone mineralization and bone density, and maintains levels of parathyroid hormone, bone resorption markers and osteoclasts. Calcium gluconate reverses LPS (HY-D1056)-induced ERK phosphorylation, inflammatory cytokine release and acute lung injury, alleviates airway inflammatory damage and suppresses immune responses. Calcium gluconate can be used in research related to postoperative myalgia, osteoporosis/osteomalacia and acute lung injury .

Cat. No.	Product Name	Target	Research Area

HY-P0090

Calcitonin (salmon) 2 Publications Verification Salmon calcitonin	CGRP Receptor	Cancer
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.

HY-P2273

Calcitonin (human)	CGRP Receptor	Metabolic Disease
Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .

HY-P0322

GRGDSPK EMD 56574	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .

HY-P1189

Echistatin	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁ .

HY-P1189A

Echistatin TFA	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁ .

HY-P1418A

DPC-AJ1951 TFA	Thyroid Hormone Receptor	Endocrinology
DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 TFA in ex vivo and in vivo assays of bone resorption .

HY-P0284A

C-telopeptide TFA	MMP	Inflammation/Immunology
C-telopeptide TFA, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD) .

HY-P1288

Protein Kinase C (530-558) PKC fragment (530-558)	PKC	Others
Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .

HY-P0284

C-telopeptide	MMP	Inflammation/Immunology
C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).

HY-P4798

Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) Human PTHrP(107-111) amide	PTHR	Others
Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) (Human PTHrP (107-111) amide) is a C-terminal parathyroid hormone-related protein fragment that can inhibit bone resorption .

HY-P0007

Elcatonin Carbocalcitonin	Drug Intermediate	Metabolic Disease
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .

HY-P0090A

Calcitonin (salmon) acetate Salmon calcitonin acetate	CGRP Receptor	Cancer
Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .

HY-P5377

Abz-HPGGPQ-EDDnp Cathepsin K substrate	Ser/Thr Protease	Others
Abz-HPGGPQ-EDDnp (Cathepsin K substrate) is a biological active peptide. (Cathepsins are a class of globular lysosomal proteases, playing a vital role in mammalian cellular turnover. They degrade polypeptides and are distinguished by their substrate specificities. Cathepsin K is the lysosomal cysteine protease involved in bone remodeling and resorption. It has potential as a drug target in autoimmune diseases and osteoporosis.This FRET peptide can be used to monitor selectively cathepsin K activity in physiological fluids and cell lysates. Abz-HPGGPQ-EDDnp [where Abz represents o-aminobenzoic acid and EDDnp represents N -(2, 4-dinitrophenyl)-ethylenediamine], a substrate initially developed for trypanosomal enzymes, is efficiently cleaved at the Gly-Gly bond by cathepsin K. This peptide is resistant to hydrolysis by cathepsins B, F, H, L, S and V, Ex/Em=340 nm/420 nm.)

HY-P1418

DPC-AJ1951	Thyroid Hormone Receptor	Endocrinology
DPC-AJ1951, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 in ex vivo and in vivo assays of bone resorption .

HY-P0322A

GRGDSPK TFA EMD 56574 TFA	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .

HY-P10237

Calcitonin (chicken)	Calcium Channel	Others
Calcitonin chicken is a hormone, that regulates calcium metabolism. Calcitonin chicken suppresses the cell motility and bone resorption in neonatal rat osteoclasts .

HY-P3530

G-{d-Arg}-GDSP	Integrin	Others
G-{d-Arg}-GDSP is an RGD peptide analogue that binds to the adhesion receptor of integrins and inhibits cellular fibronectin attachment as well as osteoclast resorption .

HY-P4684

Osteostatin PTHrP (107–111)	PTHR	Inflammation/Immunology
Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .

HY-P10299

Calcitonin, porcine	Peptides	Others
Calcitonin, porcine inhibits 1,25 (OH)₂D₃-stimulated porcine osteoclast differentiation. Calcitonin is a polypeptide hormone that can lower serum calcium by decreasing calcium reabsorption in the kidney and inhibiting osteoclastic bone resorption. Calcitonin, porcine can be used for research of hypercalcemia .

HY-P0090S

Calcitonin-13C6,15N4 (salmon) TFA Salmon calcitonin-13C6,15N4 TFA	CGRP Receptor	Metabolic Disease
Calcitonin- ¹³C₆, ¹⁵N₄ (salmon) (Salmon calcitonin- ¹³C₆, ¹⁵N₄) TFA is ¹³C and ¹⁵N-labeled Calcitonin (salmon) (HY-P0090). Calcitonin (salmon) , a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption .

HY-P4817

Human PTH-(1-31)	Thyroid Hormone Receptor	Metabolic Disease
Human PTH-(1-31) is the 1-31 fragment of human PTH. Human PTH-(1-31) stimulates the release of cAMP and also is a weaker stimulator of the 25-hydroxyvitamin D-1α-hydroxylase. Human PTH-(1-31) induces bone formation without inducing bone resorption. Human PTH-(1-31) has the potential for the research of osteoporosis .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9958

Denosumab 2 Publications Verification AMG-162	NF-κB Caspase Apoptosis RANKL/RANK	Endocrinology Cancer
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .

HY-P9982

Romosozumab 1 Publications Verification AMG-785; CDP-7851	Inhibitory Antibodies	Endocrinology Cancer
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis .

HY-P99590A

Sotatercept (mIgG2a) 1 Publications Verification RAP-011	TGF-β Receptor TGF-beta/Smad	Cardiovascular Disease Metabolic Disease
Sotatercept (mIgG2a) (RAP-011), the murine homolog of Sotatercept (ACE-011) (HY-P99590), is a soluble activin receptor type IIA (ActRIIA) ligand trap. Sotatercept (mIgG2a) inhibits the binding of activin A and other members of the TGF-β superfamily (such as Activin A/B, GDF11 and BMP9/10) to their receptors by combining and neutralizing them, thereby regulating cell proliferation and differentiation. Sotatercept (mIgG2a) mainly inhibits the SMAD2/3 signaling pathway, and can be used in various diseases such as chronic kidney disease. Sotatercept (mIgG2a) reduces the expression of erythropoietic hepcidin (ERFE), regulates iron metabolism, and promotes red blood cell production. Sotatercept (mIgG2a) has a dual effect of promoting bone formation (anabolic) and inhibiting bone resorption (catabolic) .

HY-P99186

Blosozumab	Inhibitory Antibodies	Others
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis .

HY-P9958A

Denosumab (anti-TNFSF11) 2 Publications Verification	RANKL/RANK Apoptosis NF-κB	Neurological Disease Endocrinology Cancer
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .

HY-P99291

Etaracizumab LM609; MEDI-522	Integrin Apoptosis Akt	Cancer
Etaracizumab (LM 609) is an α_vβ₃ integrin IgG mAb. Etaracizumab is developed to target α_vβ₃+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofα_vβ₃-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13653

(-)-Epigallocatechin Gallate Maximum Cited Publications 57 Publications Verification EGCG; Epigallocatechol Gallate	Structural Classification Classification of Application Fields Anti-aging Plants Endogenous metabolite Flavonoids other families Flavonones Phenols Polyphenols Inflammation/Immunology Disease Research Fields Source Classification Cancer	Endogenous Metabolite Apoptosis
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-N0721

Neoandrographolide 1 Publications Verification Neoandrographiside	Structural Classification Acanthaceae Classification of Application Fields Simsia foetida (Cav.) S.F.Blake Terpenoids Diterpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	ERK p38 MAPK JNK NF-κB PI3K PPAR GSK-3 CaMK NO Synthase Reactive Oxygen Species (ROS) Apoptosis
Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity .

HY-N0481

Roburic acid 1 Publications Verification	Triterpenes Structural Classification Gentiana macrophylla Pall. Classification of Application Fields Terpenoids Gentianaceae Plants Inflammation/Immunology Disease Research Fields Source Classification	COX TNF Receptor NO Synthase Interleukin Related NF-κB Apoptosis p38 MAPK JNK ERK Keap1-Nrf2 RANKL/RANK
Roburic acid acts as an anti-inflammatory, anti-tumor and osteoclastogenesis inhibitor, with a K_i of 7.066 μM against human TNF, an IC₅₀ of 9 μM against human COX-2, and an IC₅₀ of 5 μM against ovine COX-1. Roburic acid reduces the production of inflammatory mediators such as NO and IL-6 in macrophages by inhibiting the NF-κB and MAPK (p38/JNK) pathways. By competitively inhibiting the TNF-TNF-R1 interaction, Roburic acid blocks the downstream NF-κB signaling pathway, thereby inducing cell cycle arrest and apoptosis in cancer cells. Roburic acid specifically inhibits osteoclastogenesis and bone resorption by suppressing the RANKL/TRAF6/NF-κB/NFATc1 axis. Roburic acid can be used in research related to osteolytic diseases such as osteoporosis, colorectal cancer and inflammatory diseases .

HY-N0657

Pinoresinol Diglucoside 1 Publications Verification	Structural Classification Eucommia ulmoides Oliver Classification of Application Fields Lignans Other Diseases Eucommiaceae Phenylpropanoids Plants Disease Research Fields Source Classification	NF-κB Keap1-Nrf2 Heme Oxygenase (HO) TGF-beta/Smad Akt mTOR PI3K
Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis .

HY-N2532

Diphyllin 3 Publications Verification	Infection Monophenols Classification of Application Fields Lignans Phenols Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Inflammation/Immunology Disease Research Fields Source Classification	VSV HIV Proton Pump Influenza Virus
Diphyllin is an orally active V-ATPase inhibitor (IC₅₀=17 nM) and HIV-1 inhibitor (IC₅₀=0.38 μM). Diphyllin blocks the acidification of osteoclast lysosomes and bone resorption lacunas (IC₅₀=0.6 nM for acid influx inhibition)， thereby inhibiting bone resorption. Diphyllin can effectively inhibit osteoclast-mediated bone resorption and has no effect on osteoblastic bone formation. Diphyllin can be used in the research of bone metabolism-related diseases and has the potential to inhibit diseases related to excessive bone resorption .

HY-N0257

Epimedin A 4 Publications Verification	Flavonols Structural Classification Monophenols Flavonoids Classification of Application Fields Other Diseases Phenols Epimedium brevicornu Maxim. Plants Berberidaceae Disease Research Fields Source Classification	PI3K Akt NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Heme Oxygenase (HO) SOD Caspase Interleukin Related
Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases .

HY-N6084

Humulone α-Lupulic acid	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Humulus lupulus L. Plants Moraceae Disease Research Fields Source Classification	COX GABA Receptor Apoptosis
Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent cyclooxygenase-2 (COX-2) inhibitor. Humulone acts as a positive modulator of GABA_A receptor at low micromolar concentrations. Humulone is an inhibitor of bone resorption. Humulone possesses antioxidant, anti-angiogenic and apoptosis-inducing properties .

HY-N4288

4-Methylesculetin 3 Publications Verification	Nicotiana tabacum L. Classification of Application Fields Coumarins Phenols Polyphenols Phenylpropanoids Solanaceae Plants Disease Research Fields Source Classification Cancer	Glutathione Peroxidase Cathepsin Phosphatase
4-Methylesculetin is an orally active coumarin derivative, with potent anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits myeloperoxidase activity. 4-Methylesculetin protects bone resorption by reducing the elevated levels of bone-joint exoglycosidases, cathepsin-D and tartrate resistant acid phosphatases. 4-Methylesculetin ameliorats the upregulated non-enzymatic inflammatory markers like TNF-α, IL-1β, IL-6, COX-2 and PGE2, which is promising for research of inflammatory diseases .

HY-N0444

Rubiadin	Quinones Structural Classification Classification of Application Fields Anthraquinones Rubiaceae Phenols Polyphenols Plants Morinda officinalis How Inflammation/Immunology Disease Research Fields Source Classification	Reactive Oxygen Species (ROS)
Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .

HY-N0819

Raddeanin A 1 Publications Verification	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification Cancer	Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma .

HY-114275

Justicidin B	Acanthaceae Lignans Phenylpropanoids Plants Duhaldea wissmanniana (Hand.-Mazz.) Anderb. Source Classification	Fungal Parasite Apoptosis
Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation .

HY-108059

β-Cryptoxanthin (3R)-β-Cryptoxanthin	Other Terpenoids Structural Classification Capsicum annuum L. other families Neurological Disease Classification of Application Fields Terpenoids Solanaceae Plants Endogenous metabolite Disease Research Fields Source Classification	Drug Derivative
β-Cryptoxanthin ((3R)-β-Cryptoxanthin) is an orally active carotenoid found in fruits and vegetables such as angerines, red peppers, and pumpkin. β-Cryptoxanthin inhibits prevents osteoclast formation and inhibits bone resorption. β-Cryptoxanthin maintains retinol status in vivo. β-cryptoxanthin shows anti-inflammation and anticancer activity. β-Cryptoxanthin can be used for the researches of osteoporosis and bladder carcer .

HY-N1956

Rubiadin-1-methyl ether 1 Publications Verification	Quinones Monophenols Classification of Application Fields Anthraquinones Rubiaceae Phenols Metabolic Disease Plants Disease Research Fields Rubia cordifolia L. Source Classification	NF-κB
Rubiadin-1-methyl ether is a natural anthraquinone isolated from Morinda officinalis How, and inhibits osteoclastic bone resorption via inhibition on the phosphorylation of NF-κB p65 and the degradation of IκBα as well as decrease in the nuclear translocation of p65 .

HY-P1189

Echistatin	Natural Products Animals Classification of Application Fields Inflammation/Immunology Disease Research Fields Source Classification	Integrin
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁ .

HY-N9331

Cimicifugoside H-1 Cimicidanol-3-O-β-d-xyloside	Triterpenes Classification of Application Fields Terpenoids Ranunculaceae Metabolic Disease Plants Cimicifuga foetida Linn. Disease Research Fields Source Classification	Others
Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .

HY-N10117

2,3-Bis(3-indolylmethyl)indole	Alkaloids Hordeum vulgare var. coeleste Linnaeus Classification of Application Fields Gramineae Other Diseases Plants Disease Research Fields Indole Alkaloids Source Classification	RANKL/RANK
2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.

HY-P1189A

Echistatin TFA	Natural Products Animals Classification of Application Fields Metabolic Disease Inflammation/Immunology Disease Research Fields Source Classification	Integrin
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁ .

HY-N1746

(2S)-2'-Methoxykurarinone 2'-O-Methylkurarinone	Flavonoids Classification of Application Fields Leguminosae Flavonones Phenols Polyphenols Metabolic Disease Sophora flavescens Aiton Plants Inflammation/Immunology Disease Research Fields Source Classification	RANKL/RANK
(2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .

HY-150526

EGCG-4″-sulfate	Flavonoids Classification of Application Fields Flavanols Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification Cancer	Endogenous Metabolite Apoptosis
EGCG-4″-sulfate is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate sulfate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. EGCG-4″-sulfate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-N14323

Madindoline A	Structural Classification Natural Products Microorganisms Source Classification	Interleukin Related STAT
Madindoline A is an orally active gp130 antagonist with a K_D of 288 μM. Madindoline A inhibits IL-6- and IL-11-induced osteoclastogenesis, suppresses IL-6-stimulated serum amyloid A protein production, inhibits bone resorption and bone loss, and also inhibits IL-6- and IL-11-dependent cell line growth, as well as IL-6-dependent Stat3 tyrosine phosphorylation. Madindoline A is applicable for the research of hormone-dependent postmenopausal osteoporosis .

HY-113230B

Galactosylhydroxylysine hydrochloride 1 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Galactosylhydroxylysine hydrochloride is a component of bone collagen produced by post-translational glycosylation of hydroxylysine. Galactosylhydroxylysine hydrochloride is released during bone resorption and has been shown to be elevated in metabolic bone loss .

HY-N7646

Curculigoside B	Curculigo orchioides Gaertn. Classification of Application Fields Other Diseases Phenols Polyphenols Plants Disease Research Fields Amaryllidaceae Source Classification	Others
Curculigoside B, a phenolic glycoside isolated from Curculigo orchioides, enhances the osteoblast proliferation, decreases the area of bone resorption pit, osteoclastic formation and TRAP activity. Antiosteoporotic and antioxidative activities .

HY-129337

Reveromycin A	Infection Microorganisms Antifungal Classification of Application Fields Antibiotics Disease Research Anticancer Disease Research Fields Other Antibiotics Source Classification	Antibiotic Fungal Apoptosis
Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity .

HY-N5023

Veraguensin	Classification of Application Fields Magnoliaceae Lignans Metabolic Disease Magnolia Liliflora Desr. Phenylpropanoids Plants Disease Research Fields Source Classification	Others
Veraguensin is a lignan compound derived from Magnolia sp.. Veraguensin can inhibit bone resorption

HY-N0721R

Neoandrographolide (Standard) Neoandrographiside (Standard)	Structural Classification Acanthaceae Simsia foetida (Cav.) S.F.Blake Terpenoids Diterpenoids Plants Source Classification	Reference Standards ERK p38 MAPK JNK NF-κB PI3K PPAR GSK-3 NO Synthase Reactive Oxygen Species (ROS) Apoptosis
Neoandrographolide (Standard) is the analytical standard of Neoandrographolide. This product is intended for research and analytical applications. Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity .

HY-113230

Galactosylhydroxylysine	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Galactosylhydroxylysine is a component of bone collagen produced by post-translational glycosylation of hydroxylysine. Galactosylhydroxylysine is released during bone resorption and has been shown to be elevated in metabolic bone loss .

HY-123503

Salicortin	other families Phenols Plants Source Classification	JNK NF-κB
Salicortin, a phenolic glycoside, has been isolated from many plants such as Populus and Salix species. Salicortin inhibits osteoclast differentiation and bone resorption by down-regulating JNK and NF-κB/NFATc1 signaling pathways. Salicortin has anti-amnesic, anti-adipogenic, and immune-modulatory activity .

HY-N0257R

Epimedin A (Standard)	Flavonols Structural Classification Monophenols Flavonoids Phenols Epimedium brevicornu Maxim. Plants Berberidaceae Source Classification	Reference Standards PI3K Akt NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Heme Oxygenase (HO) SOD Caspase Interleukin Related
Epimedin A (Standard) is the analytical standard of Epimedin A (HY-N0257). This product is intended for research and analytical applications. Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases .

HY-N0481R

Roburic acid (Standard)	Triterpenes Structural Classification Gentiana macrophylla Pall. Terpenoids Gentianaceae Plants Source Classification	Reference Standards COX TNF Receptor NO Synthase Interleukin Related NF-κB Apoptosis p38 MAPK JNK ERK Keap1-Nrf2 RANKL/RANK
Roburic acid (Standard) is the analytical standard of Roburic acid. This product is intended for research and analytical applications. Roburic acid acts as an anti-inflammatory, anti-tumor and osteoclastogenesis inhibitor, with a K_i of 7.066 μM against human TNF, an IC₅₀ of 9 μM against human COX-2, and an IC₅₀ of 5 μM against ovine COX-1. Roburic acid reduces the production of inflammatory mediators such as NO and IL-6 in macrophages by inhibiting the NF-κB and MAPK (p38/JNK) pathways. By competitively inhibiting the TNF-TNF-R1 interaction, Roburic acid blocks the downstream NF-κB signaling pathway, thereby inducing cell cycle arrest and apoptosis in cancer cells. Roburic acid specifically inhibits osteoclastogenesis and bone resorption by suppressing the RANKL/TRAF6/NF-κB/NFATc1 axis. Roburic acid can be used in research related to osteolytic diseases such as osteoporosis, colorectal cancer and inflammatory diseases.

HY-N0657R

Pinoresinol Diglucoside (Standard)	Structural Classification Eucommia ulmoides Oliver Lignans Eucommiaceae Phenylpropanoids Plants Source Classification	Reference Standards NF-κB Keap1-Nrf2 Heme Oxygenase (HO) TGF-beta/Smad Akt mTOR PI3K
Pinoresinol Diglucoside (Standard) is the analytical standard of Pinoresinol Diglucoside (HY-N0657). This product is intended for research and analytical applications. Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis.

HY-N0819R

Raddeanin A (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK
Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.

Cat. No.	Product Name	Chemical Structure

HY-A0020S

Eldecalcitol-d6
Eldecalcitol-d₆ is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.

HY-B0631S

Alendronic acid-d6
Alendronic acid-d₆ is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .

HY-B0148S

Risedronic acid-d4

Risedronic acid-d₄ (Risedronate-d₄) is the deuterium labeled Risedronic acid (HY-B0148). Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC₅₀ of 20.3 μM) .

HY-108685S

Alendronate-d4 sodium
Alendronate-d₄ (sodium) (Alendronic acid-d₄ (monosodium salt)) is deuterium labeled Alendronate sodium. Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .

HY-P0090S

Calcitonin-13C6,15N4 (salmon) TFA
Calcitonin- ¹³C₆, ¹⁵N₄ (salmon) (Salmon calcitonin- ¹³C₆, ¹⁵N₄) TFA is ¹³C and ¹⁵N-labeled Calcitonin (salmon) (HY-P0090). Calcitonin (salmon) , a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption .

HY-W738852

Hydroxylysylpyridinoline-d6
Hydroxylysylpyridinoline-d₆ is deuterium labeled Pyridinoline. Pyridinoline, a fluorescent material, is a bone resorption biomarker. Pyridinoline also is a type crosslink of collagen .

HY-B0742S1

Hydroxyprogesterone caproate-d8

Hydroxyprogesterone caproate-d₈ (17α-Hydroxyprogesterone hexanoate-d₈) is the deuterium labeled Hydroxyprogesterone caproate (HY-B0742). Hydroxyprogesterone caproate (17α-Hydroxyprogesterone hexanoate; 17α-Hydroxyprogesterone caproate) is a progesterone receptor (progesterone receptor) ligand and steroid hormone transcription inhibitor. Hydroxyprogesterone caproate downregulates estrogen receptors in target tissues and activates their metabolic pathways, and exhibits equivalent affinity for progesterone receptor A and progesterone receptor B. Hydroxyprogesterone caproate shows no consistent teratogenicity or developmental toxicity in rat, mouse and monkey models, but induces resorption or abortion in rhesus monkeys at human-equivalent doses. Hydroxyprogesterone caproate promotes the production of TNF-α in lipopolysaccharide-stimulated whole blood from non-pregnant women. Hydroxyprogesterone caproate can be used in scientific research related to preterm birth .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

resorption

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products